---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-263647"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:01:30.922171+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaccinex reports pepinemab significantly reduces GFAP biomarker in Huntington's disease; presented at CTAD.

## Summary
- Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.
- Data from podium presentation at CTAD Conference in Boston on October 26, 2023.
- Prior phase 2 HD trial showed pepinemab prevented decline in glucose uptake and slowed cognitive decline (HD-CAB).
- Ongoing SIGNAL-AD trial in Alzheimer's; last patient to complete 12-month treatment expected by June 2024.
- Company sees pepinemab as potential alternative or complement to anti-Aβ antibodies for Alzheimer's.

## SEC filing metadata
- accession: 0001193125-23-263647
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/0001193125-23-263647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/d550531d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-263647
- JSON: https://secwatch.observer/filing/0001193125-23-263647.json
- Plain text: https://secwatch.observer/filing/0001193125-23-263647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.